Latest Regulatory Engagement News

Atlantic Lithium has submitted a revised Mining Lease for its Ewoyaa Lithium Project to Ghana's Parliament, incorporating updated royalty rates aligned with new legislation. The lease awaits parliamentary ratification amid evolving fiscal terms.

Boss Energy has withdrawn its 2021 Enhanced Feasibility Study for the Honeymoon uranium project due to significant deviations in resource assumptions, launching a new study focused on a wide-spaced wellfield design that could lower costs and improve recoverability.

Neurotech International has locked in $4 million through a share placement to advance its promising paediatric neurological drug, NTI164. The raise, supported by both new and existing investors including company directors, aims to fund critical clinical and regulatory milestones.

Finder Energy has completed the acquisition of the Petrojarl I FPSO, gaining full control of vital infrastructure for the Kuda Tasi and Jahal project and setting the stage for a Final Investment Decision by mid-2026.

Steadfast Group reveals robust acquisition activity and strategic cost optimizations in its latest investor update, signaling strong momentum across its Australasian and international operations.

Locksley Resources has launched an Expression of Interest process to select a leading U.S. engineering firm for the Desert Antimony Mine pilot plant design, marking a critical step toward establishing a domestic antimony supply chain aligned with federal priorities.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

Dateline Resources reaffirms the robustness of its Colosseum Gold-REE Project while denying legal claims over rare earth tenements, signaling confidence in its growth strategy.

Viridis Mining and Minerals has secured a favorable technical assessment for its Colossus Project's environmental license, setting the stage for a critical council review in December.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.

Ardea Resources updates its Definitive Feasibility Study for the Kalgoorlie Nickel Project, confirming a streamlined processing approach and a new sale product that could enhance project economics and market reach.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.